The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: A systematic review by Hazen, A.C.M. (Ankie) et al.
lable at ScienceDirect
Research in Social and Administrative Pharmacy xxx (2017) 1e13Contents lists avaiResearch in Social and Administrative Pharmacy
journal homepage: www.rsap.orgThe degree of integration of non-dispensing pharmacists in primary
care practice and the impact on health outcomes: A systematic review
Ankie C.M. Hazen, MSc a, *, Antoinette A. de Bont, PhD b, Lia Boelman, MSc a,
Dorien L.M. Zwart, MD PhD a, Johan J. de Gier Prof c, Niek J. de Wit Prof a,
Marcel L. Bouvy Prof d
a Department of General Practice, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG,
Utrecht, The Netherlands
b Institute of Health Policy and Management, Erasmus University, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands
c Department of Pharmacotherapy, Epidemiology and Economics, University of Groningen, Antonius Deusinglaan 1, Building 3214, 9713 AV, Groningen, The
Netherlands
d Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlandsa r t i c l e i n f o
Article history:
Received 23 November 2016
Received in revised form
7 April 2017
Accepted 20 April 2017
Keywords:
Clinical pharmacist
Integrated care
Primary health care
Systematic review* Corresponding author. Universiteitsweg 100, PO
3508 GA, Utrecht, The Netherlands.
E-mail addresses: a.c.m.hazen@umcutrecht.nl (A.C
nl (A.A. de Bont), lboelman@gmail.com (L. Boelm
(D.L.M. Zwart), degiercs@wxs.nl (J.J. de Gier), n.j.d
Wit), m.l.bouvy@uu.nl (M.L. Bouvy).
http://dx.doi.org/10.1016/j.sapharm.2017.04.014
1551-7411/© 2017 The Authors. Published by Elsevier
Please cite this article in press as: Hazen ACM
impact on health outcomes: A systemati
j.sapharm.2017.04.014a b s t r a c t
Background: A non-dispensing pharmacist conducts clinical pharmacy services aimed at optimizing
patients individual pharmacotherapy. Embedding a non-dispensing pharmacist in primary care practice
enables collaboration, probably enhancing patient care. The degree of integration of non-dispensing
pharmacists into multidisciplinary health care teams varies strongly between settings. The degree of
integration may be a determinant for its success.
Objectives: This study investigates how the degree of integration of a non-dispensing pharmacist impacts
medication related health outcomes in primary care.
Methods: In this literature review we searched two electronic databases and the reference list of pub-
lished literature reviews for studies about clinical pharmacy services performed by non-dispensing
pharmacists physically co-located in primary care practice. We assessed the degree of integration via
key dimensions of integration based on the conceptual framework of Walshe and Smith. We included
English language studies of any design that had a control group or baseline comparison published from
1966 to June 2016. Descriptive statistics were used to correlate the degree of integration to health
outcomes. The analysis was stratiﬁed for disease-speciﬁc and patient-centered clinical pharmacy
services.
Results: Eighty-nine health outcomes in 60 comparative studies contributed to the analysis. The accu-
mulated evidence from these studies shows no impact of the degree of integration of non-dispensing
pharmacists on health outcomes. For disease speciﬁc clinical pharmacy services the percentage of
improved health outcomes for none, partial and fully integrated NDPs is respectively 75%, 63% and 59%.
For patient-centered clinical pharmacy services the percentage of improved health outcomes for none,
partial and fully integrated NDPs is respectively 55%, 57% and 70%.
Conclusions: Full integration adds value to patient-centered clinical pharmacy services, but not to
disease-speciﬁc clinical pharmacy services. To obtain maximum beneﬁts of clinical pharmacy services for
patients with multiple medications and comorbidities, full integration of non-dispensing pharmacists
should be promoted.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).box 85500, Room Str. 6.101,
.M. Hazen), debont@bmg.eur.
an), d.zwart@umcutrecht.nl
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The aging of the population results in increasingly complex
medication-related needs.1 To sustain the economic viability of
health care the majority of elderly patients should be treated in
primary care. To incorporate speciﬁc pharmaceutical expertise,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pharmacist (NDP, also: clinical pharmacist or clinical pharmacy
specialist).
NDPs in primary care practice conduct clinical pharmacy ser-
vices (CPS) that primarily focus on chronic disease management.
CPS are usually multifaceted, including medication therapy re-
views, counselling and medication education. These services can
be aimed at patients with a speciﬁc chronic condition such as
diabetes, cardiovascular disease or COPD (“disease-speciﬁc CPS”),
or at a more heterogeneous group of patients at risk of drug
related problems, such as patients with multimorbidity and
polypharmacy (“patient-centered CPS”). Disease-speciﬁc CPS
focusses on evidence-based protocolled care, while patient-
centered CPS entails a more non-standardized and holistic
approach.2
Some NDPs are fully integrated into the health care team,3,4
whereas others only temporarily provide a speciﬁc CPS.5 Com-
mon opinion is that integrated care for patients with chronic con-
ditions may improve patient outcomes.6e8 CPS have been shown to
positively affect surrogate outcomes, such as blood pressure, gly-
cemic control and lipid goal attainment.9e13 Evidence of the effect
of CPS on clinical endpoints, such as mortality, hospitalizations and
health related quality of life, is less clear probably due to very
heterogeneously deﬁned CPS as well as strongly differing study
settings.12,14
Both aspects are features of the degree of integration of the NDP
who delivers the CPS. The degree of integration of NDPs into the
health care team may be a determinant for its success, but this
association has never been properly assessed. Therefore, we con-
ducted a systematic review to investigate how the degree of inte-
gration of an NDP impacts health outcomes in primary care.
2. Methods
The protocol of this systematic review has been published in the
PROSPERO register. The registration number is: CRD42016017506.15
2.1. Search strategy
We searched PubMed and Embase from 1966 to June 2016. A
trained librarian, in consultation with researchers, developed a
search strategy (Appendix Table 1). Also, wemanually searched the
reference list of systematic reviews and background articles about
clinical pharmacy interventions in primary care for additional
citations.
Potentially relevant studies were identiﬁed by two reviewers
(AH and LB) based on predetermined inclusion criteria in a two-
step procedure: 1) title and abstract, 2) screening of the full text.
In case disagreement about inclusion could not be resolved by
discussion between the two reviewers, a third reviewer (AB or MB)
was consulted to reach consensus. We used the PRISMA checklist to
conduct and report the systematic literature review.16
2.2. Study selection
Both USA and non-USA comparative studies of any design that
had a control group or baseline comparison were included if they
met the following criteria:
2.3. The intervention
1. comprised at least one key component of a chronic disease
management service aimed at individual ambulatory patients;
2. was conducted by an NDP who had a regular and ongoing
relationship with the primary care practice and was at leastPlease cite this article in press as: Hazen ACM, et al., The degree of integr
impact on health outcomes: A systematic review, Research in Socia
j.sapharm.2017.04.014part-time physically present and at that time not involved in
work related to community pharmacy;
3. measured a relevant clinical or patient reported health outcome
or a proxy of a relevant health outcome (e.g. improvement of
medication errors).
Studies were excluded if the intervention was delivered in a
specialty or off-site clinic without collaboration with the general
practitioner (GP), or if it was a pilot of an already included study or a
secondary analysis. Also, unpublished studies and studies pub-
lished in languages other than English were not taken into account
for analysis.
2.4. Dependant variable: degree of integration
Our main focus was the degree of integration of NDPs, which we
assessed via key dimensions of integration from the conceptual
framework of Walshe and Smith17: organizational, informational,
clinical, functional, ﬁnancial and normative integration (Table 1).
The ﬁnancial integration could not be taken into account as most
interventions were project funded studies. The key dimensions
were scored dichotomous (yes/no). A positive score on zero to two
dimensions of integration was deﬁned as “no integration”. A posi-
tive score on three or four dimensions of integrationwas deﬁned as
“partial integration” and a positive score on all ﬁve dimensions was
deﬁned as “full integration”. Prescriptive authority was taken into
account to assess clinical integration, see Table 3.
2.5. Primary outcome: health outcomes
The primary outcomes of the intervention were either real
clinical health outcomes, such as mortality, or surrogate clinical
health outcomes, such as HbA1c, lipids and blood pressure. In
addition to clinical health outcomes, we included patient reported
health outcomes, such as health related quality of life and proxies of
health outcomes, such as quality of care performance indicators.
2.6. Data collection process
Other extracted data included the duration of the intervention,
study size, primary outcomes, speciﬁcation of the CPS (disease-
speciﬁc or patient-centered) and the number of involved practices
and NDPs. The primary outcomes of the intervention were cate-
gorized as either “positive”, “negative” or “no effect”. A positive
outcome was deﬁned as a statistically signiﬁcant difference (p
value < 0.05) compared to the control group or baseline. A negative
outcome being the opposite and no effect as no statistically sig-
niﬁcant difference between intervention and control group or
baseline.
Two authors independently extracted the data and one author
cross-checked all extracted data. Differences were resolved in dis-
cussion. In case of dissensus, a third researcher was consulted. If we
were unable to score the dimensions of integration e despite
contacting the corresponding author for additional information
and verifying complementary study protocols - the study was
excluded for synthesis.
2.7. Quality assessment
We used the Effective Public Health Practice Project (EPHPP)
Quality Assessment Tool to assess: selection bias, study design,
confounders, data collection methods, withdrawals and drop-
outs. Given the nature of the included studies, blinding of the
participants and outcome assessors was generally not possible.
Therefore, this criterion was not included in the qualityation of non-dispensing pharmacists in primary care practice and the
l and Administrative Pharmacy (2017), http://dx.doi.org/10.1016/
Table 1
Key dimensions of integrated care for chronic disease management,17 tailored to the setting of a non-dispensing pharmacist in primary care practice.
Organizational: Organizational design and governance arrangements
Measurable element: an umbrella organization or network, or NDP has permanent position within primary care practice
Informational: Shared access of clinical information systems
Measurable element: GP and NDP work with integrated clinical information systems
Clinical: Delivery of rational and continuous clinical care to patients
Measurable elements: multiprofessional teams, NDP performs patient counselling and follow-up, face-to-face communication between GP
and NDP, patient directed activities outside the scope of the intervention, prescribing authority of the NDP
Functional: Supportive administrative and functional elements
Measurable element: shared education or administrative support by primary care practice staff
Financial: Financial arrangements and payment system
Measurable element: n/a
Normative: Shared vision, goals and values
Measurable element: collaboratively designed protocols with shared goals and visions of the pharmaceutical intervention
A.C.M. Hazen et al. / Research in Social and Administrative Pharmacy xxx (2017) 1e13 3assessment. Two authors independently assessed each study and
resolved disagreement by consensus or by consulting a third
reviewer.2.8. Data synthesis
The included studies were heterogeneous regarding the type of
CPS, enrolled participants, number of practices, involved NDPs and
measured health outcomes. Therefore, it was inappropriate to
perform statistical aggregation of ﬁndings. To investigate how the
degree of integration of an NDP impacts health outcomes we
plotted the number of improved primary outcomes against the
total number of assessed primary outcomes. We stratiﬁed the
analysis for disease-speciﬁc CPS and patient-centered CPS.Fig. 1. Flowchart of th
Please cite this article in press as: Hazen ACM, et al., The degree of integra
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Ninety studies were included for data extraction (Fig. 1). For
thirty studies we were unable to determine the degree of integra-
tion of the NDP and were excluded (Appendix Table 2a/b). We
grouped studies by type of CPS: disease-speciﬁc CPS (n ¼ 43) and
patient-centered CPS (n ¼ 17).
3.1. Summary of included studies
The included studies consisted of 35 RCTs, 12 two group cohort
studies and 13 one group cohort studies. The median of the study
population was 140 patients (interquartile range 76e321). The
duration of the interventions ranged from 1 to 60 months. The
median of the number of involved practices and NDPs was 1e study selection.
tion of non-dispensing pharmacists in primary care practice and the
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tively. The majority of the studies were performed in the United
Stated of America (USA) (n ¼ 43) (Tables 2a and 2b).
3.2. Methodological quality
The methodological quality was high in 18 studies (30%), mod-
erate in 34 studies (57%) and low in 8 studies (13%). 35 studies (58%)
had a strong design, with described randomization processes. Eight
studies (13%) had a high participation rate and were very likely to
be representative to the target population. Forty studies (67%)
controlled for at least 80% of relevant confounders and 48 studies
(80%) used valid and reliable data collection tools. 29 studies (48%)
had a follow-up rate of at least 80% (Table 3).
3.3. Synthesis of results
We assessed 89 health outcomes in 60 comparative studies: 54
clinical health outcomes (mainly surrogate health outcomes such
as blood pressure or HbA1c), 12 patient reported health outcomes,
such as health related quality of life and 23 proxies of health out-
comes, such as medication errors (see Table 4). CPS conducted by
NDPs showed a signiﬁcant positive effect on 62% (55/89) of
assessed health outcomes. The other 34 health outcomes showed
no statistically signiﬁcant difference compared to control group or
baseline. None of the included studies measured a negative impact
on health outcomes. The effect of CPS on surrogate clinical health
outcomes and proxies of health outcomes was high: 67% (36/54)
and 78% (18/23) of these outcomes improved. Patient reported
health outcomes were less frequently reported (n ¼ 12) and
showed improvement in one trial.
We related the dimensions of integration to the degree of
integration. We found 14 studies (23%) in which the NDPs were not
or minimally integrated into the health care team (positive score on
0e2 dimensions of integration). 71% (n ¼ 10) of NDPs had shared
access to patient medical records (informational integration). Yet,
integration on all other dimensions was low: organizational 14%
(n ¼ 2), normative 14% (n ¼ 2), functional 7% (n ¼ 1) and clinical 7%
(n ¼ 1).
We identiﬁed 19 studies (32%) in which the NDPs were partially
integrated (positive score on 3e4 dimensions of integration). All
but one (95%) had shared access to patient medical records. Inte-
gration on the clinical, functional and normative dimension was
68% (n ¼ 13) and 47% (n ¼ 9) of NDPs were permanently employed
within the practice or worked within an umbrella organization or
network (organizational integration).
We found 27 studies (45%) in which the NDPs were fully inte-
grated within the primary care practice (positive score on 5 di-
mensions of integration). This involved permanent employment
within the organization, or an umbrella organization or network,
shared information systems, shared education or administrative
support and a profound clinical role with shared goals and visions,
such as a collaborative practice agreement to enhance cooperation
in the delivery of CPS.
For each level of integration (none-partial-full), we plotted the
number of improved primary outcomes against the total number of
assessed primary outcomes (Fig. 2). The accumulated evidence
from these studies suggests that there is no impact of the degree of
integration of NDPs on health outcomes. The percentage of
improved health outcomes for none, partial and fully integrated
NDPs is respectively 63% (based on 19 assessed health outcomes
within 14 different studies), 61% (based on 23 assessed health
outcomes within 19 different studies) and 62% (based on 47Please cite this article in press as: Hazen ACM, et al., The degree of integr
impact on health outcomes: A systematic review, Research in Socia
j.sapharm.2017.04.014assessed health outcomes within 27 different studies). Also, after
stratifying the health outcomes into clinical, patient reported and
proxies of health outcomes, no association can be identiﬁed be-
tween the degree of integration of NDPs and an improvement on
health outcomes.
3.4. Stratiﬁcation of the results according to type of CPS
We included 43 studies about disease-speciﬁc CPS, in which 61
health outcomes, mainly surrogate clinical health outcomes
(n ¼ 51) were assessed, of which 67% showed a signiﬁcant positive
effect. Five patient reported health outcomes and ﬁve proxies of
health outcomes were reported, of which 20% (n ¼ 1) and 60%
(n¼ 3) showed improvement, respectively. Within this subgroup of
CPS services, we found 8 studies (19%) in which the NDPs were not
or minimally integrated into the health care team, 14 studies (33%)
inwhich the NDPs were partially integrated and 21 studies (49%) in
which the NDPswere fully integratedwithin the primary care team.
For disease-speciﬁc CPS the percentage of improved health out-
comes in studies with not, partial and fully integrated NDPs is
respectively 75%, 63% and 59%. Our data suggest a negative asso-
ciation between integration and improvement on health outcomes
for disease-speciﬁc CPS (Fig. 2).
We included 17 studies about patient-centered CPS and
assessed 28 health outcomes, mainly proxies of health outcomes
(n¼ 18) of which 83% showed a signiﬁcant positive effect. In total, 7
patient reported health outcomes were reported of which none
showed improvement. A small number of surrogate clinical health
outcomes was reported (n ¼ 3) and 2 were positively affected by
the NDP provided services. We found 6 studies (35%) in which the
NDPs were not or minimally integrated into the health care team, 5
studies (29%) in which the NDPs were partially integrated and 6
studies (35%) in which the NDPs were fully integrated within the
primary care team. For patient-centered CPS the percentage of
improved health outcomes in studies with not, partial and fully
integrated NDPs is respectively 55%, 57% and 70%. Therefore, our
data suggest a positive association between integration and
improvement on health outcomes for patient-centered CPS (Fig. 2).
4. Discussion
We evaluated the impact of the degree of integration of NDPs on
health outcomes in primary care. Although we found that the de-
gree of integration of NDPs did not impact health outcomes in the
overall group, subgroup analysis suggests that full integration of an
NDP may be especially relevant for patient-centered CPS.
An explanation of why full integration of an NDP is more
relevant for patient-centered interventions than disease-speciﬁc
interventions is provided by Weick.76 Integration enables NDPs
to manage interruptions in the care trajectory of an individual
patient. Being in close relation with both GPs and patients, NDPs
can pick up the small clues that signal lapses in the care trajectory.
The degree of integration showed a trend towards a negative as-
sociation with the health outcomes of disease-speciﬁc CPS. The
diseases-speciﬁc CPS included in this study were based upon a set
protocol. These standardized care trajectories are less prone to
errors and allowing for variety may not have an added value.
Reliability e deﬁned as compliance to the protocols e seems to be
more effective.77
Almost all studies reported surrogate health outcomes rather
than clinical endpoints such as hospitalization ormortality. Disease-
speciﬁc CPS mainly described surrogate clinical health outcomes
(e.g. HbA1c, lipids and blood pressure), while patient-centered CPSation of non-dispensing pharmacists in primary care practice and the
l and Administrative Pharmacy (2017), http://dx.doi.org/10.1016/
Table 2a
Study characteristics of disease-speciﬁc clinical pharmacy services (n ¼ 43).
Author (year) Country No.
intervention
practices/No.
NDPs
Duration
intervention
(months)
No. patients in
intervention group
Dimension of integration Primary
outcomes (effect)
Organizational Informational Clinicala Functional Normative
Diabetes (n¼16)
Choe (2005)18 USA 1/1 24 41 Yes Yes Yes Yes Yes HbA1C (þ)
Coast-Senior (1998)19 USA 2/4 3e11 23 Yes Yes Yes Yes Yes Glycemic control
(þ)
Heisler (2012)4 UK 5/11 14 1797 Yes Yes Yes Yes Yes BP (0)
Henry (2013)20 USA 1/2 3 93 Yes Yes Yes Yes Yes Guideline
adherence (0),
HbA1C (þ)
Ip (2013)21 USA 1/1 12 147 Yes Yes Yes Yes Yes HbA1c, LDL-C
and BP (þ) and
goal attainment
(þ), 10-year
CVRR (þ)
Irons (2002)22 USA 1/2 32 87 Yes No Yes No Yes Glycemic control
(0)
Jameson (2010)23 USA 13/1 12 52 No Yes No Yes Yes HbA1c (0)
McAdam-Marx (2015)24 USA 10/3 48 303 Yes Yes Yes No Yes Glycemic control
(þ)
McCord (2006)25 USA 1/1 4 316 Yes Yes Yes Yes Yes HbA1c (þ), BP
(0), lipids (þ)
McFarland (2012)26 USA 4/3 6 36 Yes No Yes Yes Yes HbA1c (0)
Mour~ao (2012)27 Brazil 6/2 6 50 No No No No No HbA1c (0)
Rothman (2005)28 USA 1/3 12 112 Yes Yes Yes Yes Yes HbA1c (þ),LDL-C
(0), BP (þ)
Salvo (2012)29 USA 1/1 18 69 Yes Yes Yes Yes Yes HbA1c (þ)
Scott (2006)30 USA 1/1 9 76 No Yes Yes Yes Yes HbA1c (þ)
Shane-McWorther (2005)31 USA 1/1 36 176 Yes Yes Yes Yes Yes HbA1c (0), lipids
(0), BP (0)
Simpson (2011)32 Canada 5/2 12 131 Yes Yes Yes Yes No BP (þ)
Hypertension (n¼11)
Bex (2011)33 USA 4/6 18 573 Yes Yes Yes Yes Yes BP (þ)
Bogden (1998)34 USA 1/1 6 49 No Yes No No No BP (þ)
Borenstein (2003)35 USA 1/1 12 98 No Yes No Yes Yes BP (þ)
Carter (2008)36 USA 5/2 9 101 Yes Yes Yes Yes Yes BP (þ)
Hirsch (2014)37 USA 1/2 9 166 No Yes Yes Yes Yes BP (þ)
Hunt (2008)38 USA 9/5 12 230 Yes Yes Yes Yes Yes BP (þ)
Magid (2013)39 USA 10/10 6 175 Yes Yes Yes Yes Yes BP (þ)
Margolis (2013)40 USA 16/8 18 228 Yes Yes Yes Yes Yes BP (þ)
Mehos (2000)41 USA 1/1 6 18 No No No No No BP (þ)
O'Neill (2014)42 USA 1/1 1 63 Yes Yes Yes Yes Yes BP (þ)
Wong (2013)43 Hong
Kong
1/? 6 92 No No No No No BP (0)
Dyslipidaemia (n¼5)
Billups (2005)44 USA 16/16-48 12 5550 Yes Yes No No Yes LDL-C (þ)
Bogden (1997)5 USA 1/1 6 47 No Yes No No No LDL-C (þ)
Smith (2013)45 USA 2/1 ? 213 Yes Yes Yes Yes Yes Lipid proﬁle
Straka (2005)46 USA 2/2 6 359 No Yes Yes No Yes LDL-C (þ)
Tahaineh (2011)47 Jordan 1/1 6 73 No No No No Yes LDL-C (þ)
Metabolic syndrome (n¼1)
Hammad (2011)48 Jordan 6/2 6 112 Yes Yes No No No Metabolic
syndrome status
(þ)
Heart failure (n¼1)
Lowrie (2012)49 UK 174/27 60 1090 No Yes Yes No No Composite of
death or hospital
admission for
worsening heart
failure (0)
Depression (n¼3)
Adler (2004)50 USA 9/5 6 268 No Yes Yes Yes No Antidepressant
use rate (þ).
depressions
severity (0)
Capoccia (2004)51 USA 1/2 12 41 Yes Yes Yes Yes Yes Depression
symptoms (0)
Finley (2003)52 USA 1/? 6 75 Yes Yes Yes Yes Yes Adherence to
antidepressant
(þ), patient
satisfaction (þ),
clinical and
functional
severity (0)
(continued on next page)
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Table 2a (continued )
Author (year) Country No.
intervention
practices/No.
NDPs
Duration
intervention
(months)
No. patients in
intervention group
Dimension of integration Primary
outcomes (effect)
Organizational Informational Clinicala Functional Normative
Osteoporosis (n¼1)
Hall (2009)53 USA 1/4 ? 22 Yes Yes Yes No Yes Compliance with
treatment
guidelines (þ)
Cardiovascular disease (n¼1)
Evans (2010)54 Canada 1/1 6 176 No Yes Yes No Yes 10 year
cardiovascular
risk reduction (0)
Diabetes þ hypertension (n¼2)
Edelman (2010)55 USA 2/2 12 133 Yes Yes Yes Yes No BP (þ),HbA1C (0)
Neto (2011)56 Brazil 1/4 36 97 Yes Yes Yes Yes Yes 10 year
cardiovascular
risk reduction (þ)
Diabetes and/or dyslipidaemia (n¼1)
Hetro (2015)57 USA 1/? 6 61 Yes Yes Yes Yes Yes HbA1C (þ), LDL-C
(0), BMI (0)
Diabetes, hypertension, dyslipidaemia or asthma (n¼1)
Koenigsfeld (2012)58 USA 3/3 13 131 þ 427þ299 þ 27 Yes Yes Yes Yes Yes Achieving goal
levels for DM (0),
hypertension (þ)
and % on asthma
controller
medication (0)
(þ) ¼ positive effect, (0) ¼ no effect, BP ¼ Blood Pressure, CVRR ¼ Cardiovascular Risk Reduction, HbA1c ¼ glycosylated haemoglobin, LDL-C ¼ low-density lipoprotein
cholesterol.
a See Appendix Table 3 for speciﬁcation.
Table 2b
Study characteristics of patient-centered clinical pharmacy services (n ¼ 17).
Author
(year)
Country No.
practices/
No. NDPs
Duration
intervention
(months)
Study size
intervention group
(patients)
Dimension of integration Primary outcome(s) (effect)
Organizational Informational Clinicala Functional Normative
Avery
(2012)59
UK 72/? 12 3812 No Yes No No No Three prescribing appropriateness
indicators (þ)
Berdine
(2012)60
USA 1/1 36 200 Yes Yes Yes Yes Yes Lipids (þ), A1C (0) and BMI (þ)
Carter
(2001)61
USA 9/51? 12 523 Yes Yes Yes Yes No Patient satisfaction (0), HRQoL (0)
Davis
(2007)62
USA 6/12 5 79 Yes Yes No Yes No MAI (þ)
Freeman
(2013)63
Australia 1/1 0e12 314 Yes Yes Yes Yes Yes Uptake of recommendations from
medication review (þ)
Galt
(1998)64
USA 1/1 12 336 Yes Yes Yes Yes Yes Reduction in use of unessential
medications (þ)
Hanlon
(1996)65
USA 1/1 12 105 No Yes No No No MAI (þ), HRQoL (0), ADE (0)
Hogg
(2009)66
Canada 1/1 12e18 121 Yes Yes Yes Yes Yes QoC for CDM (þ)
Isetts
(2006)67
USA 6/7 12 285 Yes Yes Yes Yes Yes Patients' perceptions of care (0),
HRQoL (0)
Isetts
(2008)68
USA 6/7 12 256 Yes Yes Yes Yes Yes Quality-of-care performance
measures for hypertension and
cholesterol (þ)
Krska
(2001)69
UK ?/? 3 168 No Yes No Yes No Resolved PCI (þ), HRQoL (0)
Lenander
(2014)70
Sweden 1/1 12 107 No Yes No Yes Yes Resolved MRPs (0), No. of
medications (þ)
Pindolia
(2009)71
USA 1/7 24 520 Yes Yes No No No Improvement on clinical outcome
rules (0)
Roth
(2013)72
USA ½ 6 64 No Yes No No Yes Resolved MRPs (þ)
Sellors
(2003)73
Canada 24/12 5 431 No Yes No No No No. of daily doses (0)
Tan
(2014)74
Australia 2/2 6 82 No Yes Yes Yes No Resolved MRPs (þ)
Zermansky
(2001)75
UK 4/1 12 581 No Yes No Yes Yes No. of changes to repeat prescription
changes (þ)
(þ) ¼ positive effect, (0) ¼ no effect, ADE ¼ Adverse Drug Events, BMI ¼ Body Mass Index, BP ¼ Blood pressure, CDM ¼ Chronic Disease Management, HbA1c ¼ glycosylated
haemoglobin, HRQoL ¼ Health Related Quality of Life, LDL-C ¼ low-density lipoprotein cholesterol, MAI ¼ Medication Appropriateness Index, MRP ¼ Medication Related
Problem, PCI ¼ Pharmaceutical Care Issues, QoC ¼ Quality of Care.
a See Appendix Table 3 for speciﬁcation.
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Table 3
Quality assessment of included studies.
Author (year) Selection bias Study design Confounders Data collection Drop-outs Global
Adler (2004)50 Weak Strong Strong Strong Strong Moderate
Avery (2012)59 Weak Strong Weak Strong Strong Weak
Berdine (2012)60 Moderate Moderate Weak Strong Weak Weak
Bex (2011)33 Moderate Moderate Weak Strong Moderate Moderate
Billups (2005)44 Moderate Moderate Weak Strong Strong Moderate
Bogden (1997)5 Moderate Strong Strong Strong Strong Strong
Bogden (1998)34 Moderate Strong Strong Strong Strong Strong
Borenstein (2003)35 Weak Strong Moderate Strong Strong Moderate
Capoccia (2004)51 Moderate Strong Strong Moderate Strong Strong
Carter (2001)61 Moderate Strong Weak Strong Weak Weak
Carter (2008)36 Weak Strong Strong Strong Moderate Moderate
Choe (2005)18 Strong Strong Strong Moderate Moderate Strong
Coast-Senior (1998)19 Moderate Weak Weak Moderate Strong Weak
Davis (2007)62 Strong Moderate Weak Strong Moderate Moderate
Edelman (2010)55 Weak Strong Strong Strong Strong Moderate
Evans (2010)54 Moderate Strong Strong Strong Strong Strong
Finley (2003)52 Moderate Strong Strong Strong Weak Moderate
Freeman (2013)63 Strong Moderate Weak Moderate Moderate Moderate
Galt (1998)64 Weak Moderate Weak Moderate Weak Weak
Hall (2009)53 Moderate Moderate Strong Strong Weak Moderate
Hammad (2011)48 Strong Strong Strong Strong Strong Strong
Hanlon (1996)65 Strong Strong Strong Moderate Strong Strong
Heisler (2012)4 Moderate Strong Strong Strong Weak Moderate
Henry (2013)20 Moderate Moderate Weak Weak Moderate Weak
Hetro (2015)57 Moderate Moderate Weak Strong Moderate Moderate
Hirsch (2014)37 Weak Strong Strong Strong Strong Moderate
Hogg (2009)66 Moderate Strong Strong Moderate Strong Strong
Hunt (2008)38 Weak Strong Strong Strong Weak Weak
Ip (2013)21 Moderate Moderate Strong Strong Moderate Moderate
Irons (2002)22 Moderate Moderate Strong Strong Moderate Moderate
Isetts (2006)67 Weak Moderate Moderate Strong Moderate Moderate
Isetts (2008)68 Moderate Moderate Strong Strong Weak Moderate
Jameson (2010)23 Weak Strong Strong Strong Strong Moderate
Koenigsfeld (2012)58 Moderate Moderate Weak Strong Moderate Moderate
Krska (2001)69 Moderate Strong Strong Moderate Strong Strong
Lenander (2014)70 Moderate Strong Strong Weak Moderate Moderate
Lowrie (2012)49 Weak Strong Strong Strong Strong Moderate
Magid (2013)39 Moderate Strong Strong Strong Strong Strong
Margolis (2013)40 Moderate Strong Weak Strong Strong Moderate
McAdam-Marx (2015)24 Moderate Moderate Strong Strong Moderate Moderate
McCord (2006)25 Moderate Moderate Weak Strong Moderate Moderate
McFarland (2012)26 Moderate Moderate Strong Strong Moderate Moderate
Mehos (2000)41 Moderate Strong Strong Strong Strong Strong
Mour~ao (2012)27 Strong Strong Strong Strong Moderate Strong
Neto (2011)56 Moderate Strong Strong Strong Strong Strong
O'Neill (2014)42 Moderate Weak Strong Strong Moderate Moderate
Pindolia (2009)71 Weak Moderate Weak Strong Moderate Weak
Roth (2013)72 Moderate Moderate Strong Strong Strong Moderate
Rothman (2005)28 Moderate Strong Strong Strong Strong Strong
Salvo (2012)29 Moderate Moderate Weak Strong Moderate Moderate
Scott (2006)30 Moderate Strong Strong Strong Strong Strong
Sellors (2003)73 Moderate Strong Strong Strong Strong Strong
Shane-McWorther (2005)31 Moderate Moderate Weak Strong Moderate Moderate
Simpson (2011)32 Weak Strong Strong Strong Strong Moderate
Smith (2013)45 Moderate Moderate Strong Strong Moderate Moderate
Straka (2005)46 Strong Strong Strong Strong Strong Strong
Tahaineh (2011)47 Strong Strong Weak Strong Moderate Moderate
Tan (2014)74 Moderate Moderate Strong Moderate Moderate Moderate
Wong (2013)43 Moderate Strong Strong Strong Strong Strong
Zermansky (2001)75 Weak Strong Strong Moderate Strong Moderate
Sum weak 14 (23%) 2 (3%) 18 (30%) 2 (3%) 8 (13%) 8 (13%)
Sum moderate 38 (63%) 23 (38%) 2 (3%) 10 (17%) 23 (38%) 34 (57%)
Sum strong 8 (13%) 35 (58%) 40 (67%) 48 (80%) 29 (48%) 18 (30%)
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dicators) to measure the effect of the intervention. Also, we found a
low impact of CPS on health related quality of life.51,61,65,67,69 The
effects of a multifaceted quality improvement service often do not
extend as far as to health related quality of life.78
Fully integrated NDPs are permanently employed or workPlease cite this article in press as: Hazen ACM, et al., The degree of integra
impact on health outcomes: A systematic review, Research in Socia
j.sapharm.2017.04.014within a network or umbrella organization (organizational inte-
gration), they usually have shared access to clinical information
systems (informational integration), work in multiprofessional
teams with face-to-face collaboration with the GP (clinical inte-
gration), have shared education and/or support staff for adminis-
trative functions (functional integration) and share a vision ontion of non-dispensing pharmacists in primary care practice and the
l and Administrative Pharmacy (2017), http://dx.doi.org/10.1016/
Table 4
The impact of the degree on integration of NDPs on health outcomes in primary care.
All outcomes (n ¼ 89) Disease-speciﬁc CPS (no. of assessed
outcomes: 61)
Patient-centered CPS (no. of assessed
outcomes: 28)
No
integration
Partial
integration
Full
Integration
No
integration
Partial
integration
Full
integration
No
integration
Partial
integration
Full
integration
Clinical health outcomes
Death or hospitalization 0/1 (1090) 0/1 (1090)
Surrogate clinical health outcomes
HbA1c 1/1 (50) 2/6 (687) 8/11 (1369) 1/1 (50) 2/6 (687) 8/10 (1169) 0/1 (200)
Lipids 2/2 (120) 2/2 (5909) 4/7 (1225) 2/2 (120) 2/2 (5909) 3/6 (1025) 1/1 (200)
BP 2/3 (159) 4/4 (430) 7/11 (4198) 2/3 (159) 4/4 (430) 7/11 (4198)
BMI 1/2 (261) 0/1 (61) 1/1 (200)
Metabolic syndrome status 1/1 (112) 1/1 (112)
Cardiovascular risk reduction 0/1 (176) 2/2 (244) 0/1 (176) 2/2 (244)
Subtotal 6/8 (75%) 8/13 (62%) 22/33 (68%) 6/8 (75%) 8/13 (62%) 20/30 (67%) 2/3 (67%)
Patient reported health outcomes
HRQoL 0/2 (273) 0/1 (523) 0/2 (453) 0/1 (168) 0/2 (273) 0/1 (523) 0/1 (285)
Patient satisfaction, perceptions of
care
0/1 (105) 0/1 (523) 1/2 (360) 1/1 (75) 0/1 (105) 0/1 (523) 0/1 (285)
Depression severity 0/1 (268) 0/2 (116) 0/1 (268) 0/2 (116)
Subtotal 0/3 (0%) 0/3 (0%) 1/6 (17%) 0/1 (0%) 1/4 (25%) 0/3 (0%) 0/2 (0%) 0/2 (0%)
Proxies of health outcomes
Adherence rate 1/1 (268) 1/1 (75) 1/1 (268) 1/1 (75)
Reduction of (unwanted)
medications
0/1 (431) 2/2 (688) 1/1 (336) 0/1 (431) 2/2 (688) 1/1 (336)
Medication errors, pharmaceutical
care issues, prescribing
appropriateness
6/7 (12.293) 3/4 (290) 3/5 (753) 1/1 (22) 0/2 (120) 6/7 (12.293) 2/3 (268) 3/3 (633)
Uptake of recommendations from
MR
1/1 (314) 1/1 (314)
Subtotal 6/8 (67%) 6/7 (86%) 6/8 (75%) 2/2 (100%) 1/3 (33%) 6/8 (75%) 4/5 (80%) 5/5 (100%)
Total 12/19 (63%) 14/23 (61%) 29/47 (62%) 6/8 (75%) 10/16 (63%) 22/37 (59%) 6/11 (55%) 4/7 (57%) 7/10 (70%)
No. of improved outcomes/no. of assessed outcomes (no.of intervention patients).
For each health outcome, the number of studies that demonstrated signiﬁcant improvement is divided by the total number of assessed studies. Since studies can include more
than one primary outcome, the total number of assessed outcomes (89) exceeds the total number of included studies (60).
The numbers in parentheses reﬂect the accumulated number of intervention patients in studies assessing the speciﬁc health outcome.
BP ¼ Blood pressure, BMI ¼ Body Mass Index, HbA1c ¼ glycosylated haemoglobin, HRQoL ¼ Health Related Quality of Life, MR ¼ Medication Review.
Fig. 2. Outcomes by degree of integration of NDPs on health outcomes in primary care. For each category of integration the total number of signiﬁcant improved outcomes is
divided by the total number of assessed outcomes. The results are also stratiﬁed by disease-speciﬁc CPS and patient-centered CPS.
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gration into a multidisciplinary primary care team provides greater
opportunities for both formal and informal communication, prob-
ably enhancing patient care.63 Also, expanding the clinical role of
the NDP by allocating prescribing privileges might be beneﬁcial.79
Within disease-speciﬁc CPS, more than half of the NDPs were
authorized to make medication changes within a deﬁned scope of
practice. Within patient-centered CPS, only 2 studies showed NDPs
with prescribing authority. In these kind of services, with a more
holistic approach to pharmaceutical care, prescribing authority
would entail the whole spectrum of medications. The current
absence of prescribing authority might have restricted the impact
of the CPS on health outcomes.
CPS performed in isolation may negatively inﬂuence the quality
of care.80 There is one systematic review that described the effec-
tiveness of NDPs co-located in primary care practice.9 The impor-
tance of follow-up and face-to-face communication with the
patient's GP (clinical integration) is highlighted. Other available
studies described the effectiveness of CPS in different outpatient
settings.10e14 This study is the ﬁrst to unravel the association be-
tween the extent of NDP integration in clinical care and drug
related health outcomes.
4.1. Limitations
This review has a number of limitations. Similar to most liter-
ature reviews, theremight have been publication bias. Also, CPS can
like all cognitive interventions be subject to the Hawthorne-effect.
The Hawthorne-effect might, at least partly, explain the absence of
any negative health outcome in the included studies. The in-
terventions and outcomes assessed in this review were heteroge-
neous. Also, we were unable to assess the impact of health care
systems on the degree of integration of NDPs and on the success of
the provided services. Moreover, the study population, duration of
the intervention, number of practices and involved NDPs differed
widely, limiting our options to assess the independent effect of
integration and to pool data. The problem of heterogeneity inTable 1
Search strategies for Pubmed and Embase
Pubmed search June 2016
(“pharmacist”[Title/Abstract] OR “pharmacists”[Title/Abstract] OR
“pharmaceutical service”[Title/Abstract] OR “pharmaceutical
services”[Title/Abstract] OR “pharmacy”[Title/Abstract]OR
“pharmacists”[MeSH Terms] OR “pharmaceutical services”[MeSH
Terms])
(“family practice”[Title/Abstract] OR “general practitioner”[Title/
Abstract] OR “primary care”[Title/Abstract] OR “general
practitioners”[Title/Abstract] OR “general practice”[Title/Abstract]
OR “family physician”[Title/Abstract] OR “physicians, family”[MeSH
Terms] OR “family practice”[MeSH Terms] OR “general
practitioners”[MeSH Terms] OR “general practice”[MeSH Terms])
(“patient care”[Title/Abstract]) OR “interprofessional relation”[Title/
Abstract] OR “interprofessional relations”[Title/Abstract] OR
“cooperation”[Title/Abstract] OR “collaboration”[Title/Abstract] OR
“consultation”[Title/Abstract] OR “referral”[Title/Abstract] OR
“refer”[Title/Abstract] OR “home medicines review"[Title/Abstract]
OR “medication review”[Title/Abstract] OR “medication
reviews”[Title/Abstract] OR “community dwelling”[Title/Abstract] OR
“ambulatory patient”[Title/Abstract] OR “ambulatory elderly"[Title/
Abstract] OR “ambulatory patients”[Title/Abstract] OR
“pharmaceutical care”[Title/Abstract] OR “drug utilization
review"[Title/Abstract] OR patient care[MeSH Terms] OR
interprofessional relations[MeSH Terms]OR cooperative behaviour
[MeSH Terms]OR counselling[MeSH Terms]OR professional role
[MeSH Terms] OR (referral and consultation[MeSH Terms] OR “drug
utilization review”[MeSH Terms] OR “review”[Title/Abstract])
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j.sapharm.2017.04.014clinical pharmacy intervention studies has been previously
addressed.9,12,14,81e83 Hence, we cannot draw too strong conclu-
sions about the impact of integration e as reﬂected by the wording
we choose. Lastly, the positive association we found between the
degree of integration and the effect of patient-centered CPS was
based upon a limited number of studies (n ¼ 17). Random effects
cannot be ruled out. Additional research is required when new
studies about integrated clinical pharmacy services in primary care
become available.
4.2. Implications
This study has several implications for practitioners and policy-
makers. Integration on all dimensions for all types of chronic dis-
ease management services performed by NDPs in primary care
practice may not be necessary. Integration on all dimensions should
be promoted for individually tailored, i.e. patient-centered CPS.
5. Conclusion
To obtain maximum beneﬁts of CPS for patients with multiple
medications and comorbidities, full integration of NDPs should be
stimulated.
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Appendix AEmbase search June 2016
pharmacist:ti,ab OR pharmacists:ti,ab OR pharmacy:ti,ab OR
‘pharmaceutical service’:ti,ab OR ‘pharmaceutical services’:ti,ab OR
‘pharmacist’/exp OR ‘pharmacy’/exp
‘family practice’:ti,ab OR ‘general practitioner’:ti,ab OR ‘general
practitioners’:ti,ab OR ‘general practice’:ti,ab OR ‘community
dwelling’:ti,ab OR ‘family physician’:ti,ab OR ‘community dwelling’:ti,ab
OR ‘ambulatory patient’:ti,ab OR ‘ambulatory elderly’:ti,ab OR
‘ambulatory patients’:ti,ab OR ‘primary care’:ti,ab OR ‘general practice’/
exp OR ‘general practitioner’/exp
‘patient care’:ti,ab OR ‘interprofessional relation’:ti,ab OR
‘interprofessional relations’:ti,ab OR cooperation:ti,ab OR
collaboration:ti,ab OR consultation:ti,ab OR referral:ti,ab OR refer:ti,ab
OR ‘home medicines review’:ti,ab OR ‘medication review’:ti,ab OR
'medication reviews':ti,ab OR review:ti,ab OR ‘pharmaceutical
care’:ti,ab OR ‘drug utilization review’:ti,ab OR ‘patient care’/exp OR
‘patient referral’/exp
tion of non-dispensing pharmacists in primary care practice and the
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Table 2a
excluded studies with disease-speciﬁc CPS
Author (year) Dimension of integration
Organizational Informational Clinical Functional Normative
Anaya (2008)84 No Yes Yes N/A Yes
Barnes (2014)85 Yes Yes No N/A N/A
Bruhn (2013)86 Yes Yes Yes N/A N/A
Carter (2015)87 Yes Yes Yes No N/A
Chung (2014)88 Yes Yes N/A N/A Yes
Cording (2002)89 Yes Yes N/A Yes Yes
Duran-Parrondo (2011)90 No N/A Yes N/A Yes
Erickson (1997)91 Yes Yes No N/A No
Gums (2014)92 Yes Yes Yes No N/A
Gums (2015)93 Yes Yes Yes No N/A
Jacobs (2012)94 No Yes No N/A No
Jamieson (2010)95 No Yes N/A N/A N/A
Johnson (2010)96 No N/A N/A N/A N/A
Kelly Hester (2000)97 No N/A N/A No No
Monte (2009)98 No N/A No Yes N/A
Shane-McWorther (2015)99 N/A No N/A No Yes
Solomon (1998)100 Yes N/A No N/A N/A
Stading (2009)101 Yes Yes N/A N/A N/A
Thumar (2014)102 No Yes No Yes N/A
Tobari (2010)103 Yes Yes No N/A N/A
Trompeter (2009)104 No Yes N/A Yes N/A
Villa (2009)105 N/A N/A N/A N/A N/A
Table 2b
excluded studies with patient-centered CPS
Author (year) Dimension of integration
Organizational Informational Clinical Functional Normative
Hamley (1997)106 Yes N/A N/A N/A N/A
Harris (2009)107 Yes Yes No N/A N/A
Jameson (1995)108 N/A N/A No N/A N/A
Jameson (2001)109 N/A Yes No N/A N/A
Laucka (1996)110 No Yes No N/A N/A
Lowe (2000)111 No No No N/A N/A
Morrison (2015)112 No Yes No N/A Yes
Taylor (2003)113 No Yes No N/A N/A
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Clinical integration based upon six measurable elements. The NDP was considered clinic
Ref. Patient
counselling
by NDP
Follow-up
by NDP
Face-to-face
communicat
GP and NDP
Adler (2004)50 Yes Yes Yes
Avery (2012)59 No Yes Yes
Berdine (2012)60 Yes Yes Yes
Bex (2011)33 Yes Yes Yes
Billups (2005)44 No Yes No
Bogden (1997)5 Yes No No
Bogden (1998)34 Yes No Yes
Borenstein (2003)35 Yes Yes No
Capoccia (2004)51 Yes Yes Yes
Carter (2001)61 Yes Yes Yes
Carter (2008)36 Yes Yes Yes
Choe (2005)18 Yes Yes Yes
Coast-Senior (1998)19 Yes Yes Yes
Davis (2007)62 Yes Yes No
Edelman (2010)55 Yes Yes Yes
Evans (2010)54 Yes Yes Yes
Finley (2003)52 Yes Yes Yes
Freeman (2013)63 Yes No Yes
Galt (1998)64 Yes Yes Yes
Hall (2009)53 Yes Yes No
Hammad (2011)48 Yes Yes Yes
Hanlon (1996)65 Yes No Yes
Heisler (2012)4 Yes Yes Yes
Henry (2013)20 Yes Yes Yes
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j.sapharm.2017.04.014al integrated when the result on  four elements was positive (“Yes”).
ion
Multiprofessional
collaboration
(3 care providers)
Other patient directed
activities outside scope
of intervention
Prescribing
authority
Yes Yes No
No No No
No Yes Yes
Yes Yes No
No Yes No
No No No
No No No
No No No
Yes Yes Yes
Yes Yes Yes
Yes Yes No
Yes Yes No
Yes Yes Yes
No Yes No
Yes Yes No
No Yes No
Yes Yes Yes
Yes Yes No
Yes Yes No
Yes No Yes
No No No
No No No
Yes Yes Yes
Yes Yes No
ation of non-dispensing pharmacists in primary care practice and the
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Table 3 (continued )
Ref. Patient
counselling
by NDP
Follow-up
by NDP
Face-to-face
communication
GP and NDP
Multiprofessional
collaboration
(3 care providers)
Other patient directed
activities outside scope
of intervention
Prescribing
authority
Hetro (2015)57 Yes Yes Yes Yes Yes Yes
Hirsch (2014)37 Yes Yes Yes No No Yes
Hogg (2009)66 Yes Yes Yes Yes Yes No
Hunt (2008)38 Yes Yes Yes No No Yes
Ip (2013)21 Yes Yes Yes Yes Yes Yes
Irons (2002)22 Yes Yes No No Yes Yes
Isetts (2006)67 Yes Yes Yes Yes No No
Isetts (2008)68 Yes Yes Yes Yes Yes No
Jameson (2010)23 Yes Yes Yes No No No
Koenigsfeld (2012)58 Yes Yes Yes No Yes No
Krska (2001)69 Yes Yes No Yes No No
Lenander (2014)70 Yes No Yes Yes No No
Lowrie (2012)49 Yes Yes Yes Yes No Yes
Magid (2013)39 Yes Yes No Yes Yes Yes
Margolis (2013)40 Yes Yes No Yes Yes Yes
McAdam-Marx (2015)24 Yes Yes Yes Yes No Yes
McCord (2006)25 Yes Yes Yes Yes Yes Yes
McFarland (2012)26 No Yes No Yes No Yes
Mehos (2000)41 Yes Yes No No No No
Mour~ao (2012)27 Yes Yes No No No Yes
Neto (2011)56 Yes Yes Yes Yes Yes No
O'Neill (2014)42 Yes Yes Yes Yes Yes Yes
Pindolia (2009)71 Yes Yes Yes No No No
Roth (2013)72 Yes Yes Yes No No No
Rothman (2005)28 Yes Yes Yes Yes No Yes
Salvo (2012)29 Yes Yes No Yes Yes Yes
Scott (2006)30 Yes Yes No Yes No Yes
Sellors (2003)73 Yes Yes Yes No No No
Shane-McWorther (2005)31 Yes Yes No Yes Yes No
Simpson (2011)32 Yes Yes Yes Yes No No
Smith (2013)45 Yes Yes Yes Yes Yes Yes
Straka (2005)46 Yes Yes Yes No No Yes
Tahaineh (2011)47 Yes Yes No No Yes No
Tan (2014)74 Yes No Yes Yes Yes No
Wong (2013)43 Yes No No No No No
Zermansky (2001)75 Yes Yes Yes No No No
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